Key result
Lp-PLA2 measurement reflects vascular inflammation to stratify cardiovascular disease risk.
Answers are grounded in this paper and cite their sources.
Lipoprotein-associated phospholipase A2 is an imminent reliable precise biomarker for vascular inflammation involved in the development of unstable plaques in cardiovascular diseases. The atherosclerotic plaque formation, inflammation and rupture of arterial vessels lead to heart attacks and strokes in most of the cases. The vessel-specific inflammatory enzyme, Lipoprotein-associated phospholipase A2 shoot ups in response to the rupture of arterial vessels having atherosclerotic plaques. The accurate measurement of Lipoprotein-associated phospholipase A2 envisages the individual risk of a patient and the treatment can be customized based on the result.
No takes yet. Share an insight, caveat, or question.
Thomas et al. (2021) conducted a review in Cardiovascular diseases. Lipoprotein-associated phospholipase A2 (Lp-PLA2) was evaluated. Accurate measurement of Lipoprotein-associated phospholipase A2 serves as a biomarker for vascular inflammation to envisage individual patient risk in cardiovascular diseases.
Synapse has enriched 10 related papers. Consider them for comparative context: